Evidence map›Paper›PMID 31427963›Full record

ArticleFrontiers in pharmacology2019

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.

Stavros Simeonidis, Stefania Koutsilieri, Athanassios Vozikis, David N Cooper, Christina Mitropoulou, George P Patrinos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 7 pooled it
12.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 7 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Guideline
  5. A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.Genetics in medicine : official journal of the American College of Medical Genetics · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Stavros SimeonidisDepartment of Pharmacy, University of Patras School of Health Sciences, Patras, Greece.
Stefania KoutsilieriDepartment of Pharmacy, University of Patras School of Health Sciences, Patras, Greece.
Athanassios VozikisEconomics Department, University of Piraeus, Piraeus, Greece.
David N CooperInstitute of Medical Genetics, Cardiff University, Cardiff, United Kingdom.
Christina MitropoulouThe Golden Helix Foundation, London, United Kingdom.
George P PatrinosDepartment of Pharmacy, University of Patras School of Health Sciences, Patras, Greece.
University of Patras · GRCardiff University · GBGolden Helix Foundation · GBUniversity of Piraeus · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

economic evaluationgenetic and genomic testspersonalized medicinepricingquality of lifereimbursementwillingness-to-pay

Identifiers

PMID31427963
PMCPMC6688623
OpenAlexW2965539228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.